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Abstract
Gitelman syndrome (GS), also referred to as familial hypokalemia-hypomagnesemia, is
characterized by hypokalemic metabolic alkalosis in combination with significant hypomagnesemia
and low urinary calcium excretion. The prevalence is estimated at approximately 1:40,000 and
accordingly, the prevalence of heterozygotes is approximately 1% in Caucasian populations, making
it one of the most frequent inherited renal tubular disorders. In the majority of cases, symptoms
do not appear before the age of six years and the disease is usually diagnosed during adolescence
or adulthood. Transient periods of muscle weakness and tetany, sometimes accompanied by
abdominal pain, vomiting and fever are often seen in GS patients. Paresthesias, especially in the face,
frequently occur. Remarkably, some patients are completely asymptomatic except for the
appearance at adult age of chondrocalcinosis that causes swelling, local heat, and tenderness over
the affected joints. Blood pressure is lower than that in the general population. Sudden cardiac
arrest has been reported occasionally. In general, growth is normal but can be delayed in those GS
patients with severe hypokalemia and hypomagnesemia.
GS is transmitted as an autosomal recessive trait. Mutations in the solute carrier family12, member
3 gene, SLC12A3, which encodes the thiazide-sensitive NaCl cotransporter (NCC), are found in the
majority of GS patients. At present, more than 140 different NCC mutations throughout the whole
protein have been identified. In a small minority of GS patients, mutations in the CLCNKB gene,
encoding the chloride channel ClC-Kb have been identified.
Diagnosis is based on the clinical symptoms and biochemical abnormalities (hypokalemia, metabolic
alkalosis, hypomagnesemia and hypocalciuria). Bartter syndrome (especially type III) is the most
important genetic disorder to consider in the differential diagnosis of GS. Genetic counseling is
important. Antenatal diagnosis for GS is technically feasible but not advised because of the good
prognosis in the majority of patients.
Most asymptomatic patients with GS remain untreated and undergo ambulatory monitoring, once
a year, generally by nephrologists. Lifelong supplementation of magnesium (magnesium-oxide and
magnesium-sulfate) is recommended. Cardiac work-up should be offered to screen for risk factors
of cardiac arrhythmias. All GS patients are encouraged to maintain a high-sodium and high
potassium diet. In general, the long-term prognosis of GS is excellent.
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Disease name and synonyms
Gitelman syndrome
Gitelman's syndrome
Familial hypokalemia-hypomagnesemia
Definition and epidemiology
Gitelman syndrome (GS) (OMIM 263800), also referred
to as familial hypokalemia-hypomagnesemia, is an auto-
somal recessive salt-losing renal tubulopathy that is char-
acterized by hypomagnesemia, hypocalciuria and
secondary aldosteronism, which is responsible for
hypokalemia and metabolic alkalosis [1]. The prevalence
is estimated at ~25 per million and accordingly, the prev-
alence of heterozygotes is approximately 1% in Caucasian
populations, making it one of the most frequent inherited
renal tubular disorders.
Clinical description
GS patients usually present above six years of age and in
many cases the diagnosis is only made at adult age. Most
patients suffer from tetany, especially during periods of
fever or when extra magnesium is lost due to vomiting or
diarrhea. Paresthesias, especially in the face, frequently
occur. Some patients experience severe fatigue interfering
with daily activities, while others never complain of tired-
ness. The severity of fatigue in GS is not completely related
to the degree of hypokalemia. In contrast to Bartter syn-
drome (a genetically distinct and clinically more severe
tubular transport disorder, which shares the hypokalemic
metabolic alkalosis with GS) polyuria is usually absent or
only mild. In general, growth is normal in GS patients,
however, it can be delayed in patients with severe hypoka-
lemia and hypomagnesemia [2].
Some adult GS patients suffer from chondrocalcinosis,
which is assumed to result from chronic hypomag-
nesemia. It causes swelling, local heat, and tenderness
over the affected joints. In earlier clinical reports addi-
tional symptoms, such as ataxia, vertigo, and blurred
vision have been reported.
Cruz and colleagues have challenged the generally shared
idea that GS is a mild disorder [3]. They evaluated the
symptoms and quality of life (QOL) in 50 adult patients
with molecularly proven GS and compared this cohort of
patients with 25 age- and sex-matched controls. They
found that GS patients had significantly more complaints
than controls, mainly salt craving, musculoskeletal symp-
toms such as tetany and cramps, muscle weakness and
aches, and constitutional symptoms such as fatigue, gen-
eralized weakness and dizziness, and nocturia and poly-
dipsia. In addition, measures of QOL were significantly
lower in GS patients compared to controls.
Potassium and magnesium depletion prolong the dura-
tion of the action potential of cardiomyocytes and conse-
quently increase the risk for development of ventricular
arrhythmia. Electrocardiograms of patients with Gitelman
syndrome have shown that in about 50% of cases the QT
interval is indeed slightly to moderately prolonged but,
fortunately, is not associated with clinically relevant car-
diac arrhythmias in the far majority of cases [4]. Sudden
cardiac arrest reported in few patients with GS [2,5], war-
rants systematic cardiac screening for identifying other
possible triggering mechanisms or underlying conditions.
Blood pressure in GS patients is lower than in the general
population, indicating that even the modest salt wasting
of this disease reduces blood pressure. The results from a
recent study in 35 GS-carriers (with one mutant gene
allele) suggest that GS carriers also have lower blood pres-
sure and may be protected from hypertension [6].
Another study in a large cohort also demonstrated
reduced blood pressure in subjects having SLC12A3 muta-
tions on one allele [7]. These results are distinct from a
previous study in an Amish kindred, in which no reduc-
tion of blood pressure was demonstrated in adult
patients, despite increased Na+ excretion [8]. Thus, further
studies are required to investigate whether the incidence
of cardio-vascular events differs between GS patients or
carries compared to control population.
Etiopathogenesis
In the great majority of cases GS is caused by mutations in
the solute carrier family 12, member 3, SLC12A3 gene,
which encodes the renal thiazide-sensitive sodium-chlo-
ride co-transporter NCC that is specifically expressed in
the apical membrane of cells in the first part of the distal
convoluted tubule (DCT) (reviewed in [9]). NaCl cotrans-
porter (NCC) is a polypeptide of 1021 amino acids and
the 2D-structure is predicted to contain 12 transmem-
brane domains and long intracellular amino- and carbox-
ytermini. At present, more than 140 different, putative
loss-of-function mutations in the SLC12A3  gene have
been identified in GS patients. These mutations include
missense-, nonsense-, frame-shift-, and splice-site muta-
tions and are distributed throughout the whole protein.
In general, there is extreme inter- and intrafamiliar pheno-
type variability in GS, the latter emphasizing the lack of a
correlation between the severity of symptoms in GS and
the type of mutation in the SLC12A3 gene [10]. Recently,
however, Riviera-Munoz et al. described a small subgroup
of patients with a remarkable severe phenotype, including
an early onset, severe neuromuscular manifestations,
growth retardation and ventricular arrhythmias [2]. The
majority of these patients were male and carried at least
one allele of a splice defect, resulting in a truncating tran-
script, or a non-functional intracellularly retained muta-
tion (see below). They suggested from these data that theOrphanet Journal of Rare Diseases 2008, 3:22 http://www.ojrd.com/content/3/1/22
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nature/position of the SLC12A3 mutation combined with
male gender may be a determinant factor in the severity of
GS. Studies in lager cohorts are necessary to confirm this
assumption.
By functional expression studies and results of immuno-
cytochemistry in Xenopus leavis oocytes, it was shown that
most disease-causing NCC mutants are impaired in their
routing to the plasma membrane. Thus, the majority of
mutations belong to the so-called type 2 mutations
which, in contrast to type 1 mutations that impair protein
synthesis, lead to fully synthesized proteins. These type 2
mutant proteins, however, do not traffic appropriately to
the plasma membrane, primarily due to protein misfold-
ing and retention in the endoplasmic reticulum, followed
by rapid proteoasomal degradation. De Jong and co-
workers have shown that NCC misfolding resulting in
defective trafficking in GS is not uniformly complete [11].
Some mutant NCC proteins are only partially retarded in
their trafficking; they do reach the plasma membrane,
albeit to a limited extent, and are partially active. Subse-
quently, it was demonstrated that the intrinsic activity of
these partially retarded mutants is unaffected by the muta-
tion [12,13]. This finding opens the possibility of phar-
macological chaperones, facilitating the routing of
misfolded, trafficking-defective, but otherwise functional
NCCs to the apical membrane, for therapeutic use.
Indeed, in an additional study, de Jong et al. found prove
that the transcriptional regulator 4-phenylbutyrate may
be a promising candidate for rescuing partially retarded,
but otherwise functional mutant NCCs [14]. Recently,
another class of mutations in GS was identified by Riveira-
Munoz et al. [15]. This newly identified class includes
mutants which are partly retained in the cell, but in con-
trast to the mutants mentioned above, these mutants do
not show any activity when they reach the cell surface.
A minority of patients with the Gitelman phenotype has
been shown to have mutations in the CLCNKB  gene,
encoding the renal chloride channel ClC-Kb, located in
basolateral membrane of cells of the thick ascending limb
of Henle's loop (TAL) and the distal tubules. Mutations in
the CLCNKB gene were previously found to be the cause
of classic Bartter syndrome. It is now evident that the clin-
ical phenotype in patients with CLCNKB mutations can
be highly variable, from an antenatal onset of Bartter syn-
drome on one side of the spectrum, to a phenotype closely
resembling Gitelman syndrome at the other side (review
in [9]). Therefore, there is an indication to screen the CLC-
NKB gene in patients with the Gitelman phenotype who
do not have mutations in the SLC12A3 gene.
Both loss-of-function mutations in NCC and mutations in
CLC-Kb lead to disruption of NaCl reabsorption in the
DCT (figure 1). When less NaCl is reabsorped, more
sodium will arrive in the collecting duct resulting in mild
volume contraction. The reduced vascular volume acti-
vates the renin-angiotensin-aldosterone system, increas-
ing renin activity and aldosterone levels. The elevated
aldosterone levels give rise to increased electrogenic
sodium reabsorption in the cortical collecting duct via the
epithelial sodium channel (ENaC), defending salt home-
ostasis at the expense of increased secretion of potassium
and hydrogen ions, thus resulting in hypokalemia and
metabolic alkalosis. It has been shown that passive Ca2+
reabsorption in the proximal tubule and reduced abun-
dance of the epithelial Mg2+ channel TRPM6, located in
the DCT explains thiazide-induced hypocalciuria and
hypomagnesemia, respectively [16]. Since thiazides are
known to inhibit NCC, and in view of the phenotypic
resemblance between GS and chronic thiazide-treatment,
it is very likely that similar mechanisms are involved in
the pathogenesis of respectively hypocalciuria and
hypomagnesemia seen in GS.
Diagnosis, diagnostic methods and differential 
diagnosis
The diagnosis of Gitelman syndrome is based on the clin-
ical symptoms and biochemical abnormalities. The most
typical biochemical abnormalities in GS are hypokalemia,
metabolic alkalosis, hypomagnesemia and hypocalciuria.
Serum potassium concentration is comparably low (2.7 ±
0.4 mmol/L) to Bartter syndrome. Serum magnesium con-
centration is low (less than 0.65 mmol/l). In a few GS
patients magnesium concentration is easily maintained in
the normal range early on, which may lead to a false diag-
nosis of Bartter syndrome, and only drops below normal
with time (personal observation). Urinary calcium con-
centration is usually less than 0.2 mmol/mmol creatinine
and rarely exceeds 0.5 mg/kg/day. Hypomagnesemia and
hypocalciuria have always been considered obligate fea-
tures for GS. This assumption has recently been disputed
by Lin et al. [10]. They reported two families with molec-
ularly proven GS, in which male patients had severe
hypokalemia, and were symptomatic with episodes of
paralysis, impaired urinary concentration ability, but with
normal serum magnesium and urinary calcium excretion.
Remarkably, female GS patients within these families, car-
rying the same causative mutations as the male patients,
were asymptomatic, had less severe hypokalemia, intact
urine concentration ability, but did have hypomag-
nesemia and hypocalciuria [10]. Although this was a
small study, the authors concluded that gender may affect
phenotypic expression in GS and that hypomagnesemia
and hypocalciuria may not be invariant features of the dis-
order.
Prostaglandin excretion is normal and plasma renin activ-
ity and plasma aldosterone concentration are only slightly
elevated compared to Bartter syndrome. Renal functionalOrphanet Journal of Rare Diseases 2008, 3:22 http://www.ojrd.com/content/3/1/22
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studies have demonstrated normal or slightly decreased
urinary concentrating mechanism, but clearly reduced dis-
tal fractional chloride reabsorption during hypotonic
saline infusion. GS patients have a blunted natriuretic
response to hydrochlorothiazide administration but a
prompt natriuresis after administration of furosemide,
indicating that the defect in GS is located at the level of the
distal tubule. DNA mutation analysis of the gene respon-
sible for GS may confirm the diagnosis.
Bartter syndrome is the most important genetic disorder
to consider in the differential diagnosis of GS. Especially
A model of transport mechanisms in the DCT Figure 1
A model of transport mechanisms in the DCT. Sodium-chloride (NaCl) enters the cell via the apical thiazide-sensitive 
NCC and leaves the cell through the basolateral Cl- channel (ClC-Kb), and the Na+/K+-ATPase. Indicated also are the recently 
identified magnesium channel TRPM6 in the apical membrane, and a putative Na/Mg exchanger in the basolateral membrane.
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type III Bartter syndrome, which is caused by mutations in
the CLCNKB gene, is clinically and biochemically overlap-
ping with Gitelman syndrome. The other types of Bartter
syndrome usually have an earlier onset and a more severe
phenotype.
Primary forms of renal hypomagnesemia can be distin-
guished from GS by the absence of hypokalemia. Impor-
tant acquired conditions which should be differentiated
from GS are diuretic and laxative abuse and chronic vom-
iting. The two latter conditions can be confirmed by meas-
uring of low urinary excretion of Cl-.
Genetic counseling
Genetic counseling is important. Since GS is an autosomal
recessive trait, the recurrence risk for parents with an
affected child is 25%. If the parents already have other
children, who are not obviously affected, it is not abso-
lutely sure that they do not have GS because clinical symp-
toms can appear later in life. If the parents are eager to
know the status of the other child(ren) and in case the
molecular defect in their affected child has been eluci-
dated, DNA-analysis in the other child(ren) may be per-
formed. Adult patients with GS have a low risk of having
children with GS (~1 in 400) unless the patient and his/
her partner are consanguineous. Although technically fea-
sible, antenatal diagnosis for GS is not advised and as yet
has never been asked for because of the good prognosis in
the majority of patients.
Management including treatment
Most asymptomatic patients with GS remain untreated
and undergo ambulatory monitoring (generally by neph-
rologists) with low frequency (1–2 times per year). At
each visit complaints related to hypokalemia (fatigue,
muscle weakness, constipation, cardiac arrhythmias) and
hypomagnesemia (tetany, cramps, paresthesias, joint and
muscle pain) as well as serum levels of K+, bicarbonate
and Mg2+ should be evaluated. In view of the assumption
that chondrocalcinosis is due to magnesium deficiency
(magnesium is a co-factor of various pyrophospatases,
including alkaline phosphatase), there is a clear argument
for lifelong supplementation of magnesium. Normaliza-
tion of serum magnesium is difficult to achieve since high
doses of magnesium cause diarrhea. The bio-availability
of magnesium preparations is different. Magnesium-oxide
and magnesium-sulfate have a significantly lower bio-
availability compared to magnesium-chloride, magne-
sium-lactate and magnesium-aspartate. We recommend
the administration of magnesium-chloride orally to com-
pensate for renal Mg2+ and Cl- losses. Initial daily dose is 3
mmol Mg/m2/24 hrs or 4–5 mg/kg/24 hrs. This dose
should be divided in 3–4 administrations to avoid
diarrhea and has to be adjusted according to serum mag-
nesium levels. The dose usually has to be increased during
periods of undercurrent infections especially those
accompanied by vomiting and diarrhea. In case of acute
tetany, 20% MgCl2 should be administered intravenously
(0.1 mmol Mg/kg per dose) and can be repeated every 6
hours.
Complaints related to chondrocalcinosis (mainly pseudo-
gout attacks) are caused by the deposition of calcium
pyrophosphate dehydrate crystals in synovium and the
synovial fluid and can be reduced by Mg2+ supplementa-
tion [17]. The symptoms can be controlled by non-steroi-
dal anti-inflammatory drugs (NSAID) and joint surgery is
generally not required.
If symptomatic hypokalemia is not corrected by MgCl2
administration, it can be treated by drugs that antagonize
the activity of aldosterone or block the sodium channel
ENaC in the collecting duct. We prefer the combination of
amiloride (5–10 mg/1.73 m2/day) with KCl (1–3 mmol/
kg/day divided in 3–4 doses). Amiloride should be started
with caution in order to avoid hypotension.
Growth and puberty delay in some patients with severe
GS can be corrected by adequate Mg and K supplementa-
tion and a growth-promoting effect of indomethacin was
also reported in GS patients [18]. Cardiac work-up is rec-
ommended to screen for risk factors of cardiac arrhyth-
mias. All patients with GS are encouraged to maintain a
high-sodium and high potassium diet.
Prognosis
In general, the long-term prognosis of Gitelman syn-
drome is excellent. However, the severity of fatigue may
seriously hamper some patients in their daily activities.
Progression to renal insufficiency is extremely rare in GS.
As yet, only one patient who developed chronic renal
insufficiency and subsequent progression to end-stage
renal disease has been reported [19].
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